Montai Health is a private, early-stage biotechnology company developing a platform to understand molecular interactions and tackle global challenges. The company’s unique approach incorporates big data, machine learning, multi-omics, and high-throughput screening to answer some of the biggest questions in biomedical research. Read on to learn about the company’s technology and how it’s changing the world. For more information, visit montaihealth.com or follow them on LinkedIn or Facebook.
Montai health salary
Interested in working at Montai Health? This biotechnology company is looking for an experienced Translational Biologist. As a Translational Biologist at Montai, you’ll help establish a biological testing and analysis pipeline, disease models, and other tools to improve the development of new treatments and therapies. You’ll also oversee proof of concept studies and build preclinical data packages to enable clinical studies. To learn more, read our job description and view the Montai Health salary list.
Radial therapeutics flagship
The Flagship has welcomed Luciano Rossetti as Chief Medical Officer, Head of R&D. In this role, Dr. Rossetti will work across the Flagship platforms to define and advance Flagship’s clinical portfolio. He brings more than 20 years of life sciences pharmaceutical experience, including time spent as the Global Head of Research & Development at Novartis KGaA and Editas Medicine. He previously held senior management roles in the R&D organization, including global scientific strategy for all therapeutic areas.
Flagship companies are developing new approaches to tackle major health and sustainability challenges. These approaches range from cell therapy to machine learning to microbiome-related techniques. They utilize innovative technologies to scale up their impact and reach. This ecosystem is comprised of more than 40 companies that work with Flagship platforms to develop new treatments and therapies. While most Flagship companies are focused on a particular disease area, a wide variety of therapies can be developed.
Toran therapeutics flagship
The company’s first and flagship product is a recombinant human growth hormone (rhGH) called GSK-0208. It was conceived and is in Phase 2 clinical development for the treatment of chronic kidney disease. GSK-02H is being developed by Toran Therapeutics in collaboration with a number of global pharmaceutical companies. Flagship’s portfolio is comprised of more than forty companies, which have developed innovative approaches to major health and sustainability challenges.
To develop this breakthrough medicine, the company is building a world-class R&D capability. This team has broad and deep biological expertise. It will advance medicines with speed and scientific rigor. This R&D team will provide drug development expertise across the Flagship ecosystem. To learn more about the company’s latest research, join its live webinar on February 10, 2021. It will include a panel of scientists who have been studying molecular interactions of a wide range of diseases.
The term “Montai Health” has a multi-faceted meaning. This biotechnology company develops platform technologies to understand molecular interactions and solve global challenges. Its technology incorporates tools from big data, machine learning, multi-omics, and high-throughput screening to develop novel approaches and technologies. The company’s platform is designed to help scientists find new drugs and therapeutics, which can improve the lives of millions of people around the world.
Flagship pioneering is a group of companies that develop and commercialize first-in-class life science solutions by leveraging a multidisciplinary approach to research, development, and product development. The companies in this group are creating new medicines and other life sciences solutions and are addressing global health issues with groundbreaking technologies. To date, Flagship has created and developed over 75 companies, including Moderna, which is developing a COVID-19 vaccine.
Flagship pioneering is a bioplatform innovation company focused on creating and acquiring first-in-class life sciences companies that transform human health and sustainability. Since its founding in 2000, Flagship has launched more than a hundred scientific ventures with a combined value of more than $50 billion. To date, the group has deployed more than $2.2 billion in capital, and has secured $18 billion in follow-on investments.
Flagship pioneering recently raised $1.1 billion in venture funding to support a diverse range of innovative companies focused on developing breakthrough medicines. The company’s flagship product, Generate Biomedicines, will use a machine-learning system developed under the radar over the last three years to parse the structure of thousands of human proteins and create novel protein sequences. The company’s system will also leverage generative chemistry and biology systems to produce artificially designed antibodies, enzymes, and gene-editing technologies.
Molecular nutrition is a growing science that helps protect and strengthen the body. It focuses on the biochemical changes in the body, such as amino acid metabolism and the proteomic response to pH changes. Dr. Tong earned his Bachelor of Science in animal science from Cornell University. His research interests are protein metabolism and proteomics, and he loves to ski, hike, and cook. He also enjoys learning about and studying about different cultures and their unique ways of maintaining health.
The company is a dynamic one, and the team at Montai Health is growing. He brings together significant experience in several fields, including molecular nutrition, metabolism, immunology, and machine learning. He is also the co-founder of the Montai Health foundation. In addition to his involvement in Montai, Ignacio also has co-founded Inari Agriculture and Invaio Sciences.
Montai Health is Hiring a Head of Computational Modeling at Flagship Pioneering
Montai Health is a biotechnology company focused on developing a platform to better understand molecular interactions. The company combines big data, multi-omics, and machine learning with high-throughput screening and Flagship Pioneering, which created Moderna Therapeutics. Its computational modeling group performs original model development, Bayesian statistical modeling using Stan, and machine learning using deep graph convolutional models, all of which are done with Python frameworks.
Flagship Pioneering founded
Based in Cambridge, Massachusetts, Flagship Pioneering is a venture capital firm focused on life sciences. The company conceives, resources, and develops innovative life science companies that can transform human health and sustainability. Founded in 2000, Flagship Pioneering has created more than 100 scientific ventures that have generated over $50 billion in aggregate value. The firm has raised more than $2.2 billion and received more than $18 billion in follow-on investments.
With more than $2 billion in capital, Flagship Pioneering conceives first-in-class life sciences companies. The firm’s portfolio companies have a cumulative value of over $19 billion. These companies have received over 500 patents and conducted 50 clinical trials. Their technology advances are transforming lives and addressing major health challenges. Flagship Pioneering’s portfolio companies have an unmatched track record of success, including the launch of several new medical treatments and diagnostics.
The firm is a leading incubator for life sciences ventures. Flagship Pioneering has invested in hundreds of life sciences companies, generating over $30 billion in aggregate value and over one hundred patents. The firm’s portfolio companies include Axcella, Joule, and Seres Therapeutics. Flagship is an excellent place to work to learn more about this innovative company. You can apply through our website or by contacting our internal talent acquisition team.
Flagship Pioneering is an innovative biopharmaceutical company. Founded in 2000, the company has raised more than $900 million in capital and backed companies with over $18 billion in revenue. Flagship pioneering is one of the most rapidly growing biotech companies and is ranked 12th in the world by Fortune’s Change the World list in 2021. Flagship Pioneering is looking for two dynamic individuals to join its team. First-in-category ventures include new drugs, new energy sources, and products that feed an ever-growing population.
Montai Health is an early-stage biotechnology company
As part of its scientific research team, Montai Health seeks a highly independent and interdisciplinary high-throughput biologist. The successful candidate will contribute to a variety of pipeline and platform projects, generating large amounts of data from various biological areas. The ideal candidate has experience with different cellular assays, including iPSCs. Interested candidates should also have experience with molecular genetics and cellular assays.
The company’s leadership is highly experienced in the field of biotechnology, having spent the last decade in various capacities. Formerly, he served as Chief Scientific Officer of Nirsum Laboratories, Inc., and was Co-inventor of the company’s foundational intellectual property. At Nirsum, he was a Principal Investigator on a major NIH/NIDA grant, funding the company’s mid-stage clinical studies. Prior to joining Montai Health, he was a venture capitalist at Mountain Brook Capital Management, LLC, focusing on publicly listed biopharmaceutical companies.
Dr. Fabricio Medina-Bolivar, an Arkansas graduate, worked in a university research lab. He was ready to commercialize his biotech spinoff. Fortunately, he found support through Lab2Launch Accelerator, an Arkansas-based program that assists early-stage biotechnology companies with high-quality proposals to federal programs. The first L2L-Accel cohort focused on the National Institutes of Health, while the second focused on the National Science Foundation.
While early-stage biotech companies are often associated with high growth, the upfront investment can be substantial. For example, a drug might receive regulatory approval and generate millions of dollars, but this risk comes with an increased likelihood of compound failure. Additionally, it can take many years for the drug to reach the market. As such, investors should be wary of the risks associated with biopharmaceutical development.
Q32 Bio is a cell-therapy company that is focused on developing neoantigen-specific T-cell therapies. Through its platform, Q32 Bio can isolate TCR genes from tumor biopsies. These TCR genes are often expressed by tumor-infiltrating lymphocytes, and the company believes it can engineer these genes into T-cells. Q32 Bio’s Series A financing round was valued at $40 million, and the company is focused on biologics.
Nathan Sanders is Head of Data Science at Montai Health
As the Head of Data Science at Montai Health, Nathan is responsible for the company’s predictive and statistical modeling efforts. Before joining Montai Health, Sanders worked as a science communicator and policy researcher at Flagship Pioneering and Legendary Pictures. He has also led teams at these companies, solving problems ranging from film casting to digital ad targeting. He also has extensive experience developing statistics for public health analysis and implementing participatory environmental regulation.